PPT-SOF + RBV

SOF RBV Randomisation 1 1 1 Openlabel BOSON Study SOF RBV PEGIFN for genotypes 2 and 3 18 years Chronic HCV infection Genotype 2 treatmentexperienced with cirrhosis. John J. . Faragon. , . PharmD. , BCPS, AAHIV-P. Regional Pharmacy Director, NY/NJ AETC. Pharmacist, Albany Medical Center. Objectives. Discuss recent guidelines . changes for HIV infection. Using . patient cases, discuss the role of . 400/100 mg . qd. N = 120. N = 120. W12. SOF + RBV. > . 18 years. Chronic HCV infection. Genotype . 2. Naïve . or pre-treatment. with IFN-based regimen. Compensated cirrhosis allowed**. No HBV or HIV co-infection. 400/100 mg . qd. N = 500. N = 100. W12. Placebo. >. 18 years. Chronic HCV infection. Genotype 1, 2, 4, 5 or 6. Naïve or pre-treatment. with IFN-based regimen. Compensated cirrhosis allowed**. No HBV or HIV co-infection. With Or Without Ribavirin Is Safe and Efficacious in Liver Transplant Recipients With HCV Recurrence: . Interim Results of a European Multicenter Compassionate Use Program. Herzer K,. 1. . Welzel. . 400/100/100 mg QD. N = 501. N = 440. W8. SOF/VEL 400/100 mg QD. >. 18 years. Chronic HCV infection. Genotype 1, 2, 3, 4, 5 or 6. Treatment-naïve or . IFN-experienced. Compensated cirrhosis **. allowed . Randomisation. Open-label. W8. * Liver biopsy or . Fibroscan. . > 12.5 . kPa. or . Fibrotest. . . >. 0.75 + APRI . > 2. Objective. Primary endpoint: SVR. 12 . (HCV RNA < 15 IU/mL), full analysis set . SOF + SMV + RBV. SOF + SMV. Randomisation. 2 : 1 : 2 : 1*. Open-label. * . Randomisation. was stratified on genotype (1a or 1b) in both cohorts, . IL28B . in cohort 1 and treatment history (naïve or non-responder) in cohort . 400/100/100 mg QD. N = 263. N = 152. W12. Placebo. >. 18 years. Chronic HCV infection. Genotype 1, 2, 3, 4, 5 or 6. NS5A inhibitor-experienced . for ≥ 4 weeks (exclusion if . discontinued due to an adverse. Randomisation. 1 : 1. 18-70 years. HCV genotype 1. Naïve or pre-treated. with IFN-based regimen. No cirrhosis. HCV RNA ≥ . 10.000 . IU. /ml. No prior therapy with PI. No HBV or HIV co-infection. OPTIMIST-1 Study: SMV SOF for genotype 1. Isabelle Andrieux-Meyer, MD. Médecins Sans Frontières . IAS Kuala Lumpur, July 2. nd. 2013. . Prevention strategies for HIV/HCV co infection. Epidemiological burden of HCV/HIV co-infection. Access to HCV screening. IAPAC African Regional Capacity-Building Hub. Based in Johannesburg, South Africa. Mission: Strengthen clinician capacity to deliver HIV, HBV, and HCV treatment . Partners include:. . Supported through an educational grant from: . Interim Analysis of a French Multicenter Compassionate Use Program. Christophe Hézode,. 1. Victor De Ledinghen,. 2. Helene Fontaine,. 3. Fabien Zoulim,. 4. Pascal Lebray,. 5. Nathalie Boyer,. 6. W24. SOF/VEL. >. 18 years. Chronic HCV infection. Genotype 1 to 6. Naïve or treatment-experienced. No prior treatment with . NS5A or NS5B inhibitor. Child-Pugh B cirrhosis **. No . hepatocellular. . Plus . Sofosbuvir. With or Without Ribavirin . for the Treatment of Chronic HCV . Genotype . 3 Infection: . Interim Results of a Multicenter . European Compassionate . Use . Program. Welzel. TM,.